Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, ...

Halozyme Therapeutics (NYSE:HAL) intends to finance its 2B euro ($2.1B) proposed acquisition of Germany’s Evotec (EVO) in ...

Halozyme's strategic acquisition of Evotec and innovative ENHANZE technology present growth opportunities. Click here for a ...

智通财经APP获悉，据外媒报道， 奥洛兹美医疗 (HALO.US)首席执行官海伦·托利 (Helen Torley)称，公司计划以现金形式融资20亿欧元 (合21亿美元)收购德国Evotec公司 ...

plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, according to Chief Executive Officer Helen Torley. “We feel confident in being able to fund ...

据报道，奥洛兹美医疗（HALO.US）首席执行官海伦·托利（Helen Torley）称，公司计划以现金形式融资20亿欧元（合21亿美元）收购德国Evotec公司（EVO.US）。Torley在接受采访时表示：“我们有信心以全额现金交易的方式为这笔交易提供资金。不会动用股权。她表示：“由于我们承担了一些债务，我们强劲的现金流将能够在交易完成后迅速将我们的杠杆率降至两倍。” ...

Germany’s Evotec SE has attracted takeover interest from Nasdaq-listed biotech firm Halozyme Therapeutics Inc. for a deal ...

Buying Evotec would give Halozyme other revenue streams. Helen Torley, Halozyme’s CEO, explained the offer in a statement.

Evotec surged on Friday after Halozyme Therapeutics confirmed it had submitted a non-binding proposal to buy the German ...

Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance ...

Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), to bulk up its drug discovery and development portfolio.